Allergan: Retrosense Therapeutics Acquisition (Allergan) - Sep 9, 2016 - Anticipated results from P1/2 open-label dose escalation trial (NCT02556736) in advanced retinitis pigmentosa in H2 2017; Anticipated approval for retinitis pigmentosa in 2020/2021
Anticipated P1/2 data • Anticipated regulatory • Inherited Retinal Dystrophy • Ophthalmology
|